SCHEMBL17616019

SCHEMBL17616019

Cc1ccc2[nH]c3ccccc3c(=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 1.00
POLB P06746 2/20 1.00
KMT2A Q03164 2/20 1.00
NPC1 O15118 2/20 1.00
HPGD P15428 6/20 0.67
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 5/20 0.67
GAA P10253 4/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
LMNA P02545 3/20 0.67
GLA P06280 2/20 0.67
HTT P42858 2/20 0.67
ATM Q13315 1/20 0.67
CASP6 P55212 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
ABCB1 P08183 1/20 0.63
ABCG2 Q9UNQ0 1/20 0.63
KIF11 P52732 1/20 0.61
CTSV O60911 2/20 0.57
CTSL P07711 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12039630 0.96 NPC1 (0.93) MEN1POLBKMT2ANPC1HPGD
SCHEMBL21972973 0.95 NPC1 (0.90) MEN1POLBKMT2ANPC1HPGD
SCHEMBL13933160 0.90 NPC1 (0.81) MEN1POLBKMT2ANPC1HPGD
SCHEMBL10861569 0.89 MEN1 (0.80) MEN1POLBKMT2ANPC1HPGD
SCHEMBL2756508 0.87 MEN1 (0.77) MEN1POLBKMT2ANPC1HPGD
SCHEMBL29355013 0.86 NPC1 (0.76) MEN1POLBKMT2ANPC1HPGD
SCHEMBL29475421 0.86 NPC1 (0.76) MEN1POLBKMT2ANPC1HPGD
SCHEMBL276094 0.86 NPC1 (0.76) MEN1POLBKMT2ANPC1HPGD
SCHEMBL10078171 0.85 MEN1 (0.74) MEN1POLBKMT2ANPC1HPGD
SCHEMBL30704438 0.84 MEN1 (0.73) MEN1POLBKMT2ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442779-B2 Compositions and methods for treating Friedreich's ataxia FRATAGENE THERAPEUTICS S.R.L. (IT) 2019-10-15 US disclosed
WO-2016046759-A2 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA FRATAGENE THERAPEUTICS LTD. (IT) 2016-03-31 WO disclosed
US-20160083358-A1 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA FRATAGENE THERAPEUTICS S.R.L. (IT) 2016-03-24 US disclosed
US-20160083358-A1 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA FRATAGENE THERAPEUTICS S.R.L. (IT) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083358-A1 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA ATXN10, ATXN2, ATXN2L MEN1 3654/4885POLB 1157/4885KMT2A 205/4885
US-10442779-B2 Compositions and methods for treating Friedreich's ataxia ATXN10, ATXN2, ATXN2L MEN1 3654/4885POLB 1157/4885KMT2A 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.